Skip to content
Clinical Trials – home
Therapeutic area

Infections and infestations – page 40

  • 677 clinical trials
  • 261 recruiting
  • 278 conditions
  • 27 countries

Conditions in this area

278 conditions with trials, the busiest first

Clinical trials in Infections and infestations

677 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

677 clinical trials

Study on the 9vHPV Vaccine for Preventing Oral HPV Infections in Men Aged 20-45

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:Merck Sharp & Dohme LLC

Rabies

Not recruiting

Study Comparing Intradermal and Intramuscular Rabies Vaccine Doses in Adults

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:Institute Of Tropical Medicine

COVID-19

Not recruiting

Study on the Immune Response of COVID-19 Vaccine Tozinameran with Flu Vaccine Combinations in Adults Aged 65 and Over

Registered drug
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:Tozinameran
  • Sponsor:Cr2o B.V.

Rhinovirus infection

Not recruiting

Study on 2-Deoxy-D-Glucose for Preventing Common Cold in Healthy Adults

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:2-DEOXY-D-GLUCOSE
  • Sponsor:G.ST Antivirals GmbH

Pneumonia chlamydial+2

Not recruiting

Study on the Effects of Doxycycline for Preventing Antibiotic Resistance in Patients with Bacterial STDs (Chlamydia, Gonorrhea, Syphilis)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Doxycycline Monohydrate
  • Sponsor:Institute Of Tropical Medicine

Hepatitis D+1

Not recruiting

Study on the Effects of Tobevibart and Elebsiran Compared to Bulevirtide for Patients with Chronic Hepatitis D Virus Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Vir Biotechnology Inc.

HIV infection

Not recruiting

Study on the Safety and Effectiveness of Emtricitabine and Tenofovir Alafenamide for HIV-1 Prevention in Men and Transgender Women at Risk

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Emtricitabine
  • Sponsor:Gilead Sciences Inc.

Herpes zoster

Not recruiting

Study on Long-Term Effects and Safety of Herpes Zoster Vaccine with Recombinant Varicella Zoster Virus Glycoprotein E in Older Adults

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Safety and Immune Response of PF-07831695 and a Drug Combination for Pneumococcal Infections in Healthy Toddlers Aged 12-15 Months

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal Polysaccharide Serotype 3 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
  • Sponsor:Pfizer Inc.

Study of GBS-NN/NN2 vaccine to prevent Group B streptococcus infection in healthy pregnant women: evaluating long-term immunity and booster dose safety during subsequent pregnancy

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Sponsor:Minervax ApS

HIV infection

Not recruiting

Study on Immune Response to Recombinant Zoster Vaccine in People Over 50 Living with HIV

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Study on the Safety and Immune Response of MenABCWY Vaccine in Healthy Adolescents Aged 11-14 with Meningococcal Meningitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN
  • Sponsor:GlaxoSmithKline Biologicals

Substances studied in this area

The therapies tested most often in Infections and infestations trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.